310 related articles for article (PubMed ID: 34281989)
1. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon AC; Burton LB; Chwalisz BK; Hillis J; Schaller TH; Amato AA; Betof Warner A; Brastianos PK; Cho TA; Clardy SL; Cohen JV; Dietrich J; Dougan M; Doughty CT; Dubey D; Gelfand JM; Guptill JT; Johnson DB; Juel VC; Kadish R; Kolb N; LeBoeuf NR; Linnoila J; Mammen AL; Martinez-Lage M; Mooradian MJ; Naidoo J; Neilan TG; Reardon DA; Rubin KM; Santomasso BD; Sullivan RJ; Wang N; Woodman K; Zubiri L; Louv WC; Reynolds KL
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281989
[TBL] [Abstract][Full Text] [Related]
2. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST; Semenov YR; Alloo A; Bach DQ; Betof Warner A; Bougrine A; Burton L; Cappelli LC; Castells M; Cohen J; Dewan AK; Fadden R; Guggina L; Hegde A; Huang V; Johnson DB; Kaffenberger B; Kroshinsky D; Kwatra S; Kwong B; Lacouture ME; Larocca C; Leventhal J; Markova A; McDunn J; Mooradian MJ; Naidoo J; Choi J; Nambudiri V; Nelson CA; Patel AB; Pimkina J; Rine J; Rubin KM; Sauder M; Shaigany S; Shariff A; Sullivan RJ; Zubiri L; Reynolds KL; LeBoeuf NR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599660
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
4. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
Nashed A; Zhang S; Chiang CW; Zitu M; Otterson GA; Presley CJ; Kendra K; Patel SH; Johns A; Li M; Grogan M; Lopez G; Owen DH; Li L
Cancer Immunol Immunother; 2021 Oct; 70(10):2761-2769. PubMed ID: 33625533
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
7. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
8. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
10. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes AM; Colomer-Lahiguera S; Mederos Alfonso N; Aedo-Lopez V; Spurrier-Bernard G; Tolstrup LK; Pappot H; Aspeslagh S; Rogiers A; Neyns B; Haanen JB; Mitchell SA; Addeo A; Michielin O; Eicher M
Eur J Cancer; 2021 Nov; 157():225-237. PubMed ID: 34536946
[TBL] [Abstract][Full Text] [Related]
12. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
13. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
16. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
[TBL] [Abstract][Full Text] [Related]
17. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors.
Argnani L; Casadei B; Pelusi C; Lo Preiato V; Pagotto U; Bertoni F; Zinzani PL
Sci Rep; 2022 Feb; 12(1):1753. PubMed ID: 35110658
[TBL] [Abstract][Full Text] [Related]
20. Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research.
Cheung YM; Hamnvik OR; Shariff A; Gallagher EJ
J Endocr Soc; 2023 Feb; 7(4):bvad019. PubMed ID: 36819460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
